---
document_datetime: 2023-09-21 21:18:33
document_pages: 28
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/replagal-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: replagal-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 44.7741821
conversion_datetime: 2025-12-30 01:23:53.76288
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Replagal

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                           | Opinion/ Notification 1 issued on   | Commission Decision Issued² / amended on   | Product Information affected3    | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|--------------------------------------------|----------------------------------|-----------|
| IAIN/0124/G          | Thiswas an applicationfora group of variations. A.1-Administrativechange-Changeinthename and/oraddressoftheMAH A.5.a-Administrativechange-Changeinthename and/oraddressofamanufacturer/importer | 20/09/2022                          |                                            | SmPC, Annex II, Labelling and PL |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                  | responsibleforbatchrelease                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |                        |                                |
|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------|
| I/0117           | C.I.4 -Change(s)in the SPC,Labelling orPL due to new quality,preclinical,clinicalorpharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                             | 21/07/2022 |            | SmPC, Labelling and PL |                                |
| N/0121           | Minorchangeinlabellingorpackageleafletnot connected with the SPC (Art.61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                              | 18/07/2022 |            | PL                     |                                |
| IAIN/0120/G      | Thiswasanapplicationforagroupofvariations. A.5.b-Administrative change-Change in the name and/oraddressofamanufacturer/importerofthe finished product, including quality control sites (excludingmanufacturerforbatchrelease) B.ll.b.2.c.1-Change to importer,batchrelease arrangementsandqualitycontroltestingoftheFP Replacementoradditionofamanufacturer responsibleforimportation and/orbatchrelease- Not including batch control/testing A.7-Administrativechange-Deletionof manufacturing sites | 12/05/2022 |            | Annex II and PL        |                                |
| T/0118           | TransferofMarketingAuthorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 01/03/2022 | 01/04/2022 | SmPC, Labelling and PL |                                |
| PSUSA/69/20 2108 | PeriodicSafetyUpdateEUSingleassessment- agalsidase alfa                                                                                                                                                                                                                                                                                                                                                                                                                                               | 10/03/2022 | n/a        |                        | PRACRecommendation-maintenance |
| IAIN/0119        | B.lL.b.1.a-Replacementoradditionofa manufacturingsitefortheFp-Secondarypackaging                                                                                                                                                                                                                                                                                                                                                                                                                      | 25/02/2022 | n/a        |                        |                                |

<div style=\"page-break-after: always\"></div>

|           | site                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |            |                        |                       |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------|
| IB/0116/G | This was an applicationfora group of variations. B.ll.d.2.d - Change in test procedure for the finished product-Otherchangestoatestprocedure (includingreplacementoraddition) B.1.b.2.e-ChangeintestprocedureforAsor startingmaterial/reagent/intermediate-Other changestoatestprocedure(includingreplacement oraddition)fortheASor astarting                                                                                        | 25/02/2022 | n/a        |                        | material/intermediate |
| Ⅱ/0112/G  | This was an applicationfora group of variations. B.I.b.1.f-Change in the specificationparameters and/orlimitsof anAs,starting material/intermediate/reagent-Changeoutsidethe approved specificationslimitsrangeforthe AS B.1.b.2.d-Change in testprocedureforAS or startingmaterial/reagent/intermediate-Substantial changetoorreplacementofa biological/immunological/immunochemicaltest methodoramethodusingabiologicalreagentfora | 09/09/2021 | n/a        |                        | biological AS         |
|           | A.1-Administrative change-Change in the name and/oraddressoftheMAH                                                                                                                                                                                                                                                                                                                                                                   | 26/07/2021 | 26/11/2021 | SmPC, Labelling and PL | IAIN/0114             |
| IA/0113   | A.7-Administrativechange-Deletionof manufacturingsites                                                                                                                                                                                                                                                                                                                                                                               | 29/06/2021 | n/a        |                        |                       |

<div style=\"page-break-after: always\"></div>

| IB/0111     | B.I.b.1.z-Change in the specificationparameters and/orlimitsof anAs,starting material/intermediate/reagent-Othervariation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 20/01/2021   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                     |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1/0106      | Updateofsections4.8and4.4of theSummaryof Product Characteristics(SmPC)inordertoupdate thelistofadverse drugreactions(ADRs)information basedon the finalresultsfrom studyHGT-REP-081 \" aMulticenterOpen-labelTreatmentProtocolto ObservetheSafetyofReplagal(agalsidasealfa) EnzymeReplacementTherapyinCanadianPatients withFabryDisease\"andthesafetyinformation reported in clinicaltrials.In addition,the MAH took theopportunitytointroduceeditorialandQRD changesinsectionsthroughouttheProduct InformationaccordingtotheQRDtemplatesand current guidelines,includingnewwarningsrelatedto sodium excipientandtraceabilityofbiological medicinalproducts.ThePackageLeafletis updated accordingly. C.I.4 -Change(s)in the SPC,Labelling orPL due to newquality,preclinical,clinicalorpharmacovigilance data | 26/11/2020   | 26/11/2021 | SmPC and PL | Followingreviewofthesubmitteddata,thelistofadverse drugreactions(includingfrequencies)havebeenupdated inthecorrespondingSmPCtable,takingintoaccountthe pooled data of relevantindividual clinicalstudies.In addition,safetyinformationrelatedtoclinicaltrialshasalso beenupdated accordingly. Formoreinformation,pleaserefertotheSummaryof Product Characteristics. |
| IB/0110     | B.1.b.2.a-Change in testprocedureforAS or startingmaterial/reagent/intermediate-Minor changestoanapprovedtestprocedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 30/09/2020   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                     |
| IAIN/0109/G | This was an application fora group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 06/07/2020   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|           | A.5.b-Administrative change-Change in the name and/or addressofamanufacturer/importerofthe finished product, including quality control sites (excluding manufacturerforbatchrelease) A.7-Administrativechange-Deletionof manufacturingsites B.1.b.2.z-Changein testprocedure for ASor startingmaterial/reagent/intermediate-Other variation B.lL.b.1.a-Replacementoradditionofa manufacturingsitefortheFp-Secondarypackaging site   |            |     |           |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------|
| IB/0108   | B.I.d.1.a.4-StabilityofAS-Changeinthere-test period/storage period-Extension or introduction ofa re-testperiod/storageperiodsupportedbyrealtime                                                                                                                                                                                                                                                                                     | 11/06/2020 | n/a | data      |
| IA/0107   | A.5.b-Administrativechange-Changeinthename and/oraddressofamanufacturer/importerofthe finishedproduct,includingqualitycontrolsites (excludingmanufacturerforbatchrelease)                                                                                                                                                                                                                                                           | 17/03/2020 | n/a |           |
|           | B.Il.b.1.a-Replacementoradditionofa manufacturingsitefortheFp-Secondarypackaging site                                                                                                                                                                                                                                                                                                                                               | 28/01/2020 | n/a | IAIN/0105 |
| IAIN/0104 | B.ll.b.1.a-Replacementoradditionofa manufacturing site for the Fp - Secondary packaging site                                                                                                                                                                                                                                                                                                                                        | 22/10/2019 | n/a |           |

<div style=\"page-break-after: always\"></div>

| IB/0103/G        | This was an applicationfora group of variations. B.ll.b.2.a-Change to importer,batchrelease arrangementsandqualitycontroltestingoftheFP- Replacement/additionofasitewherebatch control/testingtakesplace B.ll.b.2.a-Changetoimporter,batchrelease arrangementsandqualitycontroltestingoftheFP- Replacement/additionofasitewherebatch control/testingtakesplace   | 18/06/2019   | n/a   |                                |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|--------------------------------|
| IB/0102/G        | Thiswasanapplicationforagroupofvariations. A.7-Administrativechange-Deletionof manufacturingsites A.7-Administrative change-Deletion of manufacturingsites B.ll.b.2.a-Change to importer,batchrelease arrangementsandqualitycontroltestingoftheFP- Replacement/additionofasitewherebatch control/testingtakesplace                                               | 27/03/2019   | n/a   |                                |
| PSUSA/69/20 1808 | PeriodicSafetyUpdateEu Single assessment- agalsidase alfa                                                                                                                                                                                                                                                                                                        | 14/03/2019   | n/a   | PRACRecommendation-maintenance |
| IB/0100          | B.ll.b.5.c-Change to in-processtestsorlimits appliedduring themanufactureofthefinished product-Deletionofanon-significantin-processtest                                                                                                                                                                                                                          | 22/11/2018   | n/a   |                                |
| IB/0101/G        | Thiswas an applicationfora groupof variations.                                                                                                                                                                                                                                                                                                                   | 21/11/2018   | n/a   |                                |

<div style=\"page-break-after: always\"></div>

| B.Ia.4.b-Change to in-processtests or limits applied during the manufacture of the AS - Addition ofanewin-processtestandlimits B.I.a.4.z-Change toin-process tests orlimits applied during the manufacture of the As - Other variation B.I.a.4.z-Change to in-process tests orlimits applied during the manufacture of the As - Other variation                  |            |     |           |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------|
| Thiswasanapplicationforagroupofvariations. A.5.b-Administrative change-Change in the name and/oraddressofamanufacturer/importerofthe finished product, including quality control sites (excludingmanufacturerforbatchrelease) A.7-Administrativechange-Deletionof manufacturingsites                                                                             | 17/08/2018 | n/a | IA/0098/G |
| Thiswasanapplicationforagroupofvariations. B.1.b.1.b-Changeinthespecificationparameters and/or limits of an As, starting material/intermediate/reagent-Tighteningof specification limits B.lL.d.1.c-Changein the specificationparameters and/orlimitsofthefinishedproduct-Additionofa newspecificationparametertothespecificationwith itscorrespondingtestmethod | 17/01/2018 | n/a | IA/0097/G |

<div style=\"page-break-after: always\"></div>

| IAIN/0096        | B.lL.b.2.c.1-Change to importer,batchrelease arrangements andqualitycontroltestingoftheFP- Replacementoradditionofamanufacturer responsibleforimportation and/orbatchrelease- Not includingbatch control/testing                                                                                               | 21/11/2017   | 25/10/2018   | AnnexIIand PL          |                                |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|--------------------------------|
| IA/0095          | A.5.b-Administrative change-Change in the name and/oraddressofamanufacturer/importerofthe finishedproduct,including qualitycontrol sites (excludingmanufacturerforbatchrelease)                                                                                                                                | 11/11/2016   | n/a          |                        |                                |
| IA/0094/G        | Thiswasanapplicationforagroupofvariations. A.4-Administrative change-Change in thename and/oraddressofamanufactureroranAsMFholder orsupplieroftheAs，startingmaterial,reagentor intermediateusedinthemanufactureoftheASor manufacturerofanovelexcipient A.7-Administrativechange-Deletionof manufacturing sites | 15/09/2016   | n/a          |                        |                                |
| 600/NI           | A.1-Administrative change-Change in the name and/oraddressoftheMAH                                                                                                                                                                                                                                             | 14/07/2016   | 06/10/2016   | SmPC, Labelling and PL |                                |
| PSUSA/69/20 1508 | PeriodicSafetyUpdateEu Single assessment- agalsidase alfa                                                                                                                                                                                                                                                      | 11/02/2016   | n/a          |                        | PRACRecommendation-maintenance |
| IB/0092/G        | This was an applicationfora group of variations. B.I.b.1.c-Change in the specification parameters and/or limits of an As, startinq                                                                                                                                                                             | 14/01/2016   | n/a          |                        |                                |

<div style=\"page-break-after: always\"></div>

|           | material/intermediate/reagent-Additionofanew specificationparameterto thespecificationwithits correspondingtestmethod B.1.b.2.e-ChangeintestprocedureforAsor startingmaterial/reagent/intermediate-Other changestoa testprocedure(includingreplacement or addition)for the As or a starting material/intermediate B.lL.b.5.a-Change toin-processtestsorlimits applied duringthemanufactureofthefinished product-Tightening ofin-processlimits   |            |            |                 |                                                                                                                                                                                            |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0091 | B.Il.b.2.c.1-Changetoimporter,batchrelease arrangements andqualitycontroltestingoftheFP- Replacementoradditionofamanufacturer responsibleforimportationand/orbatchrelease- Notincludingbatchcontrol/testing                                                                                                                                                                                                                                     | 21/10/2015 | 06/10/2016 | Annex II and PL |                                                                                                                                                                                            |
| IG/0621   | C.I.8.a-Introductionoforchangestoasummaryof Pharmacovigilancesystem-ChangesinQPPV (including contactdetails)and/orchangesinthe PSMF location                                                                                                                                                                                                                                                                                                    | 16/10/2015 | n/a        |                 |                                                                                                                                                                                            |
| IB/0088   | B.I.a.2.a-Changesinthemanufacturingprocessof theAS-Minor changeinthemanufacturingprocess oftheAS                                                                                                                                                                                                                                                                                                                                                | 10/08/2015 | n/a        |                 |                                                                                                                                                                                            |
| S/0086    | 13thAnnualRe-assessment                                                                                                                                                                                                                                                                                                                                                                                                                         | 21/05/2015 | n/a        |                 | TheCHMP,havingreviewedtheevidenceofcompliance withthespecificobligationsandhavingreassessedthe impactofdatasubmittedaspartofthisannualre- assessment,considersthatthebenefit/riskbalanceof |

<div style=\"page-break-after: always\"></div>

|                  |                                                                                                                                                                                                                                                                |            |            |                        | Replagalremainspositiveandtherefore,recommendsby consensus the variation to the terms of the Marketing Authorisationforthemedicinalproduct. Inaddition,theCHMPconsidersthatall specificobligations havenowbeenfulfilledandthere arenoremaininggrounds fortheMarketingAuthorisationtoremainunderexceptional circumstances. ThedataprovidedbytheLTER5yearoutcomestudyare considered robust and reliable. Theyprovide further long termefficacyandsafetydataontheuseofReplagalin patients with Fabry disease treated with a 0.2 mg Eow regimen. Therefore the specific obligation 041.6 1a is now consideredfulfilled. ItisagreedthatafurtheraLow-DoseMaintenanceClinical Studywouldbedifficulttoperformandwouldnotadd furthervalue,tothecurrentknowledgegatheredthrough literature and registrysince initial approval. AmendmentsareintroducedintheSmPCsection5.1reflect thecurrentknowledgewiththeuseofalowermaintenance dose (0.1 mg/kg/body weight).   |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/69/20 1408 | PeriodicSafetyUpdateEu Singleassessment- agalsidase alfa                                                                                                                                                                                                       | 12/02/2015 | n/a        |                        | PRACRecommendation-maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| I/0084/G         | Thiswasanapplicationforagroupofvariations. C.I.4 -Change(s)in the SPC,Labelling orPL due to newquality,preclinical,clinicalorpharmacovigilance data C.I.4 -Change(s) in the SPC,Labelling or PL due to newquality,preclinical,clinicalorpharmacovigilance data | 24/07/2014 | 10/02/2015 | SmPC, Annex IⅡI and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IB/0085/G   | This was an applicationfora group of variations.   | 13/06/2014   | n/a   |
|-------------|----------------------------------------------------|--------------|-------|

<div style=\"page-break-after: always\"></div>

|           | B.I.b.1.z-Change in the specificationparameters and/or limits of an As, starting material/intermediate/reagent-Othervariation B.I.b.1.z-Changeinthespecificationparameters and/orlimits of anAs,starting material/intermediate/reagent-Othervariation                                                                                                                                      |            |            |                                 |                                                                                                                                                                                                   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0080    | Annualre-assessment.                                                                                                                                                                                                                                                                                                                                                                       | 23/01/2014 | 21/03/2014 | AnnexIⅡI                        |                                                                                                                                                                                                   |
| I/0083    | C.I.4 -Change(s)in the SPC,Labelling orPL due to newquality,preclinical,clinicalorpharmacovigilance data                                                                                                                                                                                                                                                                                   | 20/02/2014 | 10/02/2015 | SmPC, Annex I, Labelling and PL |                                                                                                                                                                                                   |
| PSUV/0081 | PeriodicSafetyUpdate                                                                                                                                                                                                                                                                                                                                                                       | 06/02/2014 | n/a        |                                 | PRACRecommendation-maintenance                                                                                                                                                                    |
| IB/0082/G | Thiswas anapplicationfora groupof variations. B.lL.b.2.a-Change toimporter,batchrelease arrangements andqualitycontroltestingoftheFP- Replacement/additionofasitewherebatch control/testingtakesplace B.ll.d.2.b-Change in testprocedure for the finished product-Deletionofatestprocedureifan alternativemethodisalreadyauthorised A.7-Administrativechange-Deletionof manufacturingsites | 03/01/2014 | n/a        |                                 |                                                                                                                                                                                                   |
| 1/0078    | Updateofsection5.1oftheSmPCasrequested by theCHMPafterassessmentofspecificobligationS02 041.51b(final analysisof data inpatients enrolled in studyTKT028）inordertoaddinformationonvarious                                                                                                                                                                                                  | 21/11/2013 | 21/03/2014 | SmPC,Annex I, Labelling and PL  | Withthesubmissionoffinalstudyreportfrom theclinical study ontheuse ofvariousdosingregimentsofReplagal, importantclinical databecameavailableandtheCHMP requestedtheupdateofsection5.1oftheSmPCand |

<div style=\"page-break-after: always\"></div>

|         | dosingregimen.ThePackageLeafletisupdated accordingly. Furthermore,thePIisbeingbroughtinlinewiththe latestQRDtemplateversion9.0andtoupdateAnnex IIinordertoreflectthefulfilmentoftwospecific obligations. Therequestedvariationproposedamendmentsto theSummary of Product Characteristics,Annex II, Labelling andPackage Leaflet. C.I.4-Variationsrelatedtosignificantmodifications of theSPC dueinparticularto new quality,pre- clinical,clinicalorpharmacovigilancedata   |            |            |                        | Patient Leaflet.Thisstudywassubmitted infulfilmentof a specific obligation. The benefit-riskbalance of Replagal remainspositive.                                                                                                  |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0077 | B.ll.e.5.b-Change in pack size of the finished product-Deletionofapacksize(s)                                                                                                                                                                                                                                                                                                                                                                                              | 14/08/2013 | 21/03/2014 | SmPC, Labelling and PL |                                                                                                                                                                                                                                   |
| S/0075  | Annual Reassessment.                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 25/04/2013 | n/a        |                        | TheCHMP,havingreviewedtheevidenceofcompliance withthespecificobligationssubmittedbytheMAHand havingre-assessedthebenefit/riskprofileofthemedicinal product,concluded thatthebenefit/riskbalanceforthe product remains favourable. |
| WS/0291 | Thiswas an applicationforavariationfollowinga worksharingprocedure accordingtoArticle20of CommissionRegulation(EC)No1234/2008. B.I.a.1.e-ChangeinthemanufacturerofASorofa startingmaterial/reagent/intermediateforAs-The changerelatestoabiologicalAsorastarting material[-lusedinthemanufactureofa                                                                                                                                                                        | 21/02/2013 | n/a        |                        |                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|           | biological/immunologicalproduct                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |      |                                                                                                                                                                                                                                                                                                  |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1/0076    | Updateofsection5.1oftheSmPCinordertoadd safetyinformationfromtheinterimreportofstudy HGT-REP-059,summarising the resultsfrom this prospectivelydefinedinterim analysisofthe12 monthexperienceofopen-label Replagal AF(Animal Freeprocess)treatmentinuSpatients withFabry disease andtoincludeinformation onpatients switchedfromFabrazymetoReplagal.Minor formattingchangeshavebeenimplementedin sections,4.8，5.1,5.2and6.5oftheSmPC. Therequestedvariationproposedamendmentsto theSummaryofProductCharacteristics. C.I.4-Variationsrelated to significant modifications of theSPCdueinparticulartonewquality,pre- | 17/01/2013 | 01/07/2013 | SmPC | Basedonthepreliminaryresultsavailablefromtheon- going clinical study HGT-REP-059, the MAH proposed to update section5.1oftheSmPCofReplagal.This informationisofinterestforpatientsandtreatingphysician asitindicatesthat(short-term)safetyisnotcompromised by theswitchfromFabrazyme toReplagal. |
| IA/0073/G | This wasan applicationfora group of variations. B.Ia.4.a-Change to in-processtests orlimits applied during the manufacture of the AS - Tightening ofin-process limits B.I.a.4.b-Changetoin-processtestsorlimits applied duringthemanufactureof theAS-Addition ofanewin-processtest andlimits                                                                                                                                                                                                                                                                                                                       | 19/09/2012 | n/a        |      |                                                                                                                                                                                                                                                                                                  |
| IG/0216   | C.I.z - Changes (Safety/Efficacy) of Human and VeterinaryMedicinalProducts-Othervariation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 14/09/2012 | n/a        |      |                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| IB/0072   | B.ll.b.2.a-Change tobatchrelease arrangements andqualitycontroltestingoftheFP-Replacement oradditionofasitewherebatchcontrol/testing takesplace                                                                                                                                                                                                                                            | 14/09/2012   | n/a        |           |                                                                                                                                                                                                                                    |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0175/G | This was an applicationfora group of variations. A.4-Administrative change-Changein the name and/or addressofamanufacturerorsupplierofthe AS,startingmaterial,reagentorintermediateused in themanufactureoftheAS A.5.b-Administrative change-Change in the name and/oraddressofamanufacturerofthefinished product, including quality control sites (excluding manufacturerforbatchrelease) | 04/06/2012   | 17/09/2012 | Annex II  |                                                                                                                                                                                                                                    |
| S/0068    | Annualreassessment                                                                                                                                                                                                                                                                                                                                                                         | 15/12/2011   | 17/02/2012 | Annex II  | TheCHMP,havingreviewed theevidenceofcompliance withthespecificobligationssubmittedbytheMAHand havingre-assessedthebenefit/riskprofileofthemedicinal product,concluded thatthebenefit/riskbalanceforthe product remains favourable. |
| IB/0067   | C.I.3.a-Implementationof change(s)requested followingtheassessmentofanUsR,classlabelling,a PSUR,RMP,FUM/SO,data submittedunderA 45/46, or amendmentstoreflectaCoreSPC-Changeswith NOnewadditionaldata are submitted bytheMAH                                                                                                                                                               | 07/12/2011   | 17/02/2012 | SmPCandPL |                                                                                                                                                                                                                                    |
| 1/0066    | Changeinthemanufactureroftheactivesubstance. B.I.a.1.e-ChangeinthemanufacturerofAsorofa startingmaterial/reagent/intermediateforAs-The                                                                                                                                                                                                                                                     | 23/06/2011   | 23/06/2011 |           |                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|          | changerelatestoabiologicalAsorastarting material[-] usedinthemanufactureofa biological/immunologicalproduct                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|
| 1/0064   | Change in the specificationparametersofthe finished product. B.ll.d.1.e-Change in the specificationparameters and/or limits of the finished product- Change outsidetheapprovedspecificationslimitsrange                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 19/05/2011 | 19/05/2011 |
| Ⅱ/0063/G | Thiswasanapplicationforagroupofvariations. Additionof manufacturingsitesresponsibleforthe manufacturingprocessofthefinishedproduct. Change in thebatchsize of thefinishedproduct. B.lL.b.1.c-Replacementor additionofa manufacturing sitefortheFp-Sitewhere any manufacturingoperation(s)takeplace,exceptbatch release,batchcontrol,andsecondarypackaging,for biological/immunologicalmedicinalproducts. B.lL.b.4.f -Change in the batch size (including batch sizeranges)ofthefinishedproduct-Thescalefor a biological/immunologicalmedicinalproduct is increased/decreased without process change (e.g. duplicationofline) B.ll.b.2.a-Change tobatchrelease arrangements andqualitycontroltestingoftheFP-Replacement or addition ofa site where batch control/testing | 17/03/2011 | 29/03/2011 |

<div style=\"page-break-after: always\"></div>

|         | B.Il.b.1.a-Replacementoradditionofa manufacturingsitefortheFp-Secondarypackaging site B.ll.b.2.a-Change tobatchrelease arrangements andqualitycontroltestingoftheFP-Replacement or addition ofa site where batch control/testing takes place B.ll.b.2.a-Change tobatchrelease arrangements andqualitycontroltestingoftheFp-Replacement or addition ofa site where batch control/testing takesplace B.ll.b.2.a-Change tobatchrelease arrangements andqualitycontroltestingoftheFP-Replacement oradditionofasitewherebatchcontrol/testing takes place   |            |            |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|
| IB/0062 | B.lL.b.4.f-Change inthebatch size(including batch sizeranges)ofthe finishedproduct-The scalefora biological/immunological medicinal product is increased/decreased without process change (e.g. duplication ofline)                                                                                                                                                                                                                                                                                                                                   | 14/03/2011 | n/a        |
| S/0060  | Annualre-assessment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 16/12/2010 | 07/01/2011 |
| IG/0029 | A.5.b-Administrativechange-Changeinthename and/oraddressofamanufacturerofthefinished product, including quality control sites (excluding manufacturerforbatchrelease)                                                                                                                                                                                                                                                                                                                                                                                 | 02/12/2010 | n/a        |
| 1/0058  | Additionof alternativestorageofcellbanksandGMP storage facility.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 23/09/2010 | 29/09/2010 |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | B.Ia.1.e-ChangeinthemanufacturerofAsorofa startingmaterial/reagent/intermediateforAs-The changerelatestoabiologicalAsorastarting material [-] usedinthemanufactureof a biological/immunological product                                                           |            |            |                 |                                                                                                                                                                                                                                                                                            |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1/0056  | Additionofamanufacturerresponsibleforbatch releasetestingofthefinishedproduct. 01_Change inor additionof manufacturing site(s)for partorallofthemanufacturingprocess                                                                                              | 24/06/2010 | 01/07/2010 |                 |                                                                                                                                                                                                                                                                                            |
| IA/0059 | B.lL.b.2.b.1-Change tobatch release arrangements andqualitycontroltesting oftheFP-Notincluding batch control/testing                                                                                                                                              | 24/06/2010 | n/a        | Annex II and PL |                                                                                                                                                                                                                                                                                            |
| IB/0057 | Extensionofthelongtermstorageperiodofthe unpurified bulk active substance intermediate. B.I.d.1.a.4-StabilityofAS-Changeinthere-test period/storage period-Extension or introduction ofa re-testperiod/storageperiodsupported byrealtime data                     | 16/02/2010 | n/a        |                 |                                                                                                                                                                                                                                                                                            |
| 1/0054  | Updateofsections4.2,4.4，4.8and5.1of the SummaryofProductCharacteristicstoinclude details emergingfromstudyTKT-029.Additionally,sections 4.4and4.8wereupdatedtoincluderelevant informationfromacumulativereviewofcardiac eventsuptoAugust2008.Section2ofthePackage | 19/11/2009 | 22/12/2009 | SmPC and PL     | TheMAHhasperformedalongtermpaediatricextension study(TKT029)in17childrenaged8.5to18yearsto assessthesafetyofenzymereplacementtherapy(ERT) withReplagalinFabrydisease.TheresultsofstudyTKT029 indicatethattheeffectsofReplagaltreatmenton manifestationsofFabrydiseaseinchildren7-18yearsof |

<div style=\"page-break-after: always\"></div>

|         | Leaflethavebeenupdated accordingly. UpdateofSummaryofProductCharacteristicsand PackageLeaflet   |            |     | ageare consistent with thosereportedinadults.The pharmacokineticresultswere asexpected,and itwas concludedthatReplagalisclearedfasterfromcirculationin children(7-18) thenin adults.Althoughthe data interpretationoftherenalefficacy endpoint(eGFR) and the painendpointislimitedbythesmallsamplesize,the observedeffectssuggestanimprovementovertimefor bothvariables.The adversedrugreactions(ADRs)reported inthestudyweresimilarto thoseseeninthe adult population and represent symptoms commonly seen in patientswithFabrydisease.Basedontheobservationsin thestudytheCHMPrecommendedanupdateofsections 4.2,4.4,4.8and5.1oftheSPC. TheMAHalsoperformedareviewoncardiaceventsand Replagalinfusions.Thereview didnotrevealany causal associationofcardiaceventswithReplagal.However,it wasnoted than thatinpatientswithpre-existing cardiac manifestations ofFabrydisease,infusionreactionsmaybe associatedwithhemodynamicstresstriggeringacardiac event.TheCHMPthereforerecommended anupdateof sections4.4and4.8toincludearelevantwarning.   |
|---------|-------------------------------------------------------------------------------------------------|------------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0055  | Annual re-assessment.                                                                           | 17/12/2009 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IA/0053 | IA_o5_Changeinthenameand/oraddressofa manufacturerofthefinishedproduct                          | 04/09/2009 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IA/0052 | IA_o7_a_Replacement/add.of manufacturingsite: Secondarypackagingsite                            | 24/06/2009 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| 1/0050   | Change indrug substance manufacturing process. Change(s)to themanufacturingprocessforthe activesubstance                                                                                                | 23/04/2009   | 28/04/2009   |                        |                                                                                                                                                                                                     |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1/0051   | Additionofnewqualitycontrollaboratoryand change innameof anexisting manufacturer. Change(s)to themanufacturingprocessforthe activesubstance Change(s)to the manufacturingprocessforthe finished product | 19/12/2008   | 23/03/2009   |                        |                                                                                                                                                                                                     |
| S/0048   | Annualre-assessment.                                                                                                                                                                                    | 18/12/2008   | n/a          |                        |                                                                                                                                                                                                     |
| IA/0049  | IA_01_Change in thename and/oraddressof the marketingauthorisationholder                                                                                                                                | 31/10/2008   | n/a          | SmPC, Labelling and PL |                                                                                                                                                                                                     |
| IB/0047  | IB_36_a_Changein shape or dimensionsofthe container/closure-sterileph.forms/biologicals                                                                                                                 | 17/10/2008   | n/a          |                        |                                                                                                                                                                                                     |
| IA/0046  | IA_22_a_SubmissionofTSEPh.Eur.certificatefor exc.-Approved/newmanufacturer                                                                                                                              | 11/04/2008   | n/a          |                        |                                                                                                                                                                                                     |
| I/0045   | Change(s) to the manufacturing process for the activesubstance                                                                                                                                          | 19/03/2008   | 26/03/2008   |                        |                                                                                                                                                                                                     |
| S/0043   | Annualre-assessment.                                                                                                                                                                                    | 13/12/2007   | 05/03/2008   | SmPCandPL              | TheCHMP,havingreviewedtheevidenceofcompliance withthespecificobligationssubmittedbytheMarketing Authorisation Holderand havingre-assessedthe benefit/riskprofileofthemedicinalproduct,concludesthat |

<div style=\"page-break-after: always\"></div>

|         |                                                                                        |            |            |                        | overall,thebenefit/riskratiofortheproductremains unchanged.The CHMP considered that the Marketing AuthorisationforReplagalshouldremainunderexceptional circumstancesinviewofthependingspecificobligations. Additionally,the section 4.4 \"Special warnings and precautions foruse\"of the SPC has been amended to relatedreaction. TherelevantsectioninthePackageLeaflethasbeen updated.                                                                                                                       |
|---------|----------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| I/0044  | Change(s)to themanufacturingprocessforthe finishedproduct                              | 13/12/2007 | 21/12/2007 |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 1/0041  | Change(s)to thetest method(s)and/or specificationsfortheactivesubstance                | 18/10/2007 | 24/10/2007 |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| IA/0042 | IA_08_b_01_Change inBR/QC testing-repl./add. manuf.responsibleforBR-notincl.BC/testing | 17/09/2007 | n/a        | Annex II and PL        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| S/0037  | Fifthannualre-assessment                                                               | 14/12/2006 | 12/02/2007 | SmPC, Labelling and PL | TheCHMP,havingreviewedtheevidenceofcompliance with thespecificobligationssubmitted bytheMarketing AuthorisationHolderandhavingre-assessedthe benefit/riskprofileofthemedicinalproduct,concludesthat, overall,thebenefit/riskratiofortheproductremains unchanged.The CHMP considered that the Marketing AuthorisationforReplagalshouldremainunderexceptional circumstancesinviewofthependingspecificobligations. Additionally,anupdateofthenumberofpregnancies exposedtoReplagal(n=4)insection4.6oftheSummary |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|        |                                                                                                                                                                                                                                                                                                                  |            |            |      | Product Characteristics and corresponding sectionofthe Package Leafletwas made.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1/0035 | Thisvariationrelatestoanupdateofsections4.2 and5.1oftheSummaryofProductCharacteristicsto includelongtermefficacydatawithregardstorenal function,cardiacfunction andlifequality enhancementbasedonseveralstudiessummarized inthe3rdAnnualReassessment. EMEA/H/C/369/S/25. UpdateofSummaryofProductCharacteristics | 18/10/2006 | 24/11/2006 | SmPC | ChangesintheSPCsection4.2Posology andmethodof administrationandsection5.1Pharmacodynamic properties.These changes are based on data accumulated sincethegrantingof theMarketingAuthorisation andthat havepreviouslybeenreportedin clinical studyreports submittedtotheCHMPorinanalysesthatwere summarizedinthe3rdAnnualReassessment EMEA/H/C/369/S/25. Thefollowinginformation included in theReplagal SPCis basedonthecombinedanalysisoftheeffectoflong-term ReplagaltherapyonrenalfunctioninadultFabrypatients enrolledinthestudiessubmittedtotheEMEAaspartofthe initialapplicationandtheclinicalstudyreportsforstudies were submitted and assessed post marketing. Changesrelated totherenalfunction Updateofsection4.2Posology andmethodof administrationoftheReplagal Spcforend-stagerenal disease(ESRD)andsection5.1 asfollows. 4.2 Posologyandmethodofadministration Patientswithrenalimpairment Nodoseadjustmentisnecessaryinpatientswithrenal impairment. Thepresenceofextensiverenaldamage(eGFR <60mL/min)maylimittherenalresponsetoenzyme replacementtherapy.Limited data are available inpatients ondialysisorpost-kidneytransplantation,nodose |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         |                                                                                                                                                                                                                                                                                       |            |            |                                | adjustmentisrecommended. Andsection5.1Pharmacodynamicproperties \"Longer term therapy(48-54 months) resulted in stabilisationofGFRinmalepatientswithnormalbaseline GFR(=90mL/min/1.73m2)andwithmildtomoderate renaldysfunction(GFR60to<90mL/min/1.73m2),and inslowingoftherateofdeclineinrenalfunctionand progression to end-stage renal disease in male Fabry patientswithmoresevererenaldysfunction(GFR30to< 60 mL/min/1.73 m2).\" Changesrelatedtocardiacfunction TheMAHproposed changestosection5.1basedon the combinedanalysisofLeftVentricular(Lv)masschanges withlong-termReplagaltherapyin adultFabrypatients.   |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0036 | IA_01_Change in the name and/oraddressof the marketingauthorisationholder                                                                                                                                                                                                             | 13/09/2006 | n/a        | SmPC,Annex I, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| I/0034  | Thisvariationreferstoanupdateofrelevantsections oftheSummaryProductCharacteristics(SPC)to includeinformationonpaediatricpatientsfurtherto thefourthannualreassessment.Corresponding sectionofthePackageLeaflet(PL)was amended accordingly. UpdateofSummaryofProductCharacteristicsand | 27/07/2006 | 01/09/2006 | SmPCandPL                      | Duringthefourthannualreassessment,theCHMPreviewed dataontheuseofReplagalinpaediatricpatients(7-18 years)andrecommendedtoreflectthisinformationinto theSummaryProductCharacteristics(SPC).Therefore,the Marketing Authorisation Holder (MAH) submitted this type IIvariationtoupdaterelevantsectionsoftheSPCandalso proposedto amend section2 of the Package Leaflet(PL) accordingly.TheCHMPconsideredthesechangestobe                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|        | Package Leaflet                                                                                                                                                                                                                                                                      |            |            |                                | acceptable.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| I/0033 | Thisvariationrefersto anupdate of section4.6of theSummaryProductCharacteristics(SPC)to include information on pregnancy further to the fourthannualreassessment.Section2ofthe PackageLeaflet(PL)was amended accordingly. UpdateofSummaryofProductCharacteristics and Package Leaflet | 27/07/2006 | 01/09/2006 | SmPC and PL                    | Duringthefourthannualreassessment,theCHMPreviewed data on pregnancy exposure toReplagalandrecommended toincludethesedataintotheSPC.Therefore,theMAH submitted thistypeIIvariationtomentioninsection4.6of theSPCthatverylimitedclinicaldataonpregnancies exposedtoReplagal(n=3)have shownno adverseeffects on themotherornewborn child.Section2ofthePLwas amendedaccordingly.TheCHMPconsideredthesechanges tobe acceptable.                                                                                          |
| R/0030 | Renewalofthemarketing authorisation.                                                                                                                                                                                                                                                 | 01/06/2006 | 28/07/2006 | SmPC,Annex I, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| I/0031 | Change(s) to the manufacturing process for the active substance                                                                                                                                                                                                                      | 28/06/2006 | 03/07/2006 |                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| S/0029 | Annualreassessment: Fourthannualre-assessment.                                                                                                                                                                                                                                       | 14/12/2005 | 09/02/2006 | Annex II and PL                | TheCHMP,havingreviewedtheevidenceofcompliance withthespecificobligationssubmitted bytheMarketing Authorisation Holderandhavingre-assessedthe benefit/riskprofileofthemedicinalproduct,concluded that,overall,thebenefit/riskratiofortheproductremains unchangedandrecommendsthatnoamendmentof AnnexesI andmlof theCommissionDecisionisnecessary. Thelistof Specificobligationsis setoutinAnnexI.Cand hasbeenrevisedaccordingtotheconclusionsoftheCHMP discussion. TheCHMPconsideredthattheMarketingAuthorisationfor |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                  |            |            |                                 | Replagalshouldremainunderexceptional circumstancesin viewofthepending SpecificObligations.                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1/0028  | Change(s)to themanufacturingprocessforthe activesubstance                                                                                                                        | 17/11/2005 | 22/11/2005 |                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 1/0027  | RevisionoftheSummary ofProductCharacteristics, section4.4and4.8，andcorrespondingupdateof PackageLeaflet,sections2and4. UpdateofSummaryofProductCharacteristicsand PackageLeaflet | 23/06/2005 | 27/07/2005 | SmPCand PL                      | Followingtheassessmentofthe5thPsuRand the3rd AnnualRe-assessment,theMAHrevisedthewordingsof sections4.4and4.8oftheSummaryofProduct Characteristics (SPC) and sections 2 and 4 of the Package Leaflet(PL). The sections were also revised in generalto reflectcurrentavailabledata.                                                                                                                                                                                                            |
| S/0025  | Third annual re-assessment.                                                                                                                                                      | 15/12/2004 | 03/03/2005 | SmPC, Annex Ⅱ, Labelling and PL | TheCHMP,havingreviewedtheevidenceofcompliance withthespecificobligationssubmitted bytheMarketing AuthorisationHolderand havingre-assessed the benefit/riskprofileofthemedicinalproduct,concluded that,overall,thebenefit/riskratiofortheproductremains unchangedandrecommendsthatnoamendmentof AnnexesI andloftheCommissionDecisionisnecessary. TheCHMPconsideredthattheMarketingAuthorisationfor Replagalshouldremainunderexceptional circumstancesin viewof thepending SpecificObligations. |
| IA/0026 | IA_o1_Changeinthenameand/oraddressofthe marketingauthorisationholder                                                                                                             | 18/11/2004 | n/a        | SmPC, Labelling and PL          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 1/0022  | New presentation(s)                                                                                                                                                              | 24/03/2004 | 29/07/2004 | SmPC, Labelling and PL          | TheCPMPconsideredthisTypeIIvariationontheaddition ofanew1.0mlpresentation(1.0mg/ml)inpacksizesof1, 4 and 10 vials tobe acceptable.                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| I/0023   | Updateofsection4.4oftheSummaryofProduct Characteristics,concerningtheeffectsofrenal functioninpatients withextensiverenaldamage. QRDeditorialchangeswereintroducedinsection6.4 of SPC.TheLabelling andthePackageLeafletwere updated. UpdateofSummaryofProductCharacteristics, Labelling andPackageLeaflet   | 26/02/2004   | 20/07/2004   | SmPC, Labelling and PL   | Asaresultofthesecond annualre-assessmentforReplagal inOctober2003theMAHwasrequestedtosubmitatypeII variationinordertoadjusttheSPCtoincludereferenceto therapybeingprobablylesseffectiveinpatientswith extensiverenaldamage.Thenewtextwasconsidereda warning and therefore included in section4.4.Additionally, thesection6.4wasrevisedtotakeaccountofthemost recent changesto the QRD. The Labelling and the Package leaflet were consequently updated.                        |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| I/0024   | Change(s)to shelf-life orstorage conditions                                                                                                                                                                                                                                                                 | 24/03/2004   | 31/03/2004   |                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 1/0021   | Change(s)to themanufacturingprocessforthe finished product Change(s)to thetestmethod(s)and/or specificationsfortheactivesubstance                                                                                                                                                                           | 24/03/2004   | 31/03/2004   |                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| S/0019   | Annualre-assessment.                                                                                                                                                                                                                                                                                        | 22/10/2003   | 16/01/2004   | Annex IⅡI                | TheCPMP,havingreviewed theevidenceofcompliance withthespecificobligationssubmitted bytheMarketing Authorisation Holderand havingre-assessed the benefit/riskprofileofthemedicinalproduct,concluded that,overall,thebenefit/riskratiofortheproductremained unchangedandrecommendedthatnoamendmentof AnnexesIandⅢloftheCommissionDecisionwas necessary.The MarketingAuthorisationforReplagal should remainunderexceptionalcircumstancesinviewofthe pending Specific Obligations. |
| IB/0020  | IB_37_b_Changein the specificationofthefinished product-add.ofnewtestparameter                                                                                                                                                                                                                              | 10/11/2003   | n/a          |                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|        | InclusionofsevereinfusionreactionsintheSPC，and changesresultingfromchangingthewHoART98.3 UpdateofSummaryofProductCharacteristics   | 26/06/2003   | 03/10/2003   | SmPC     | 1/0018 dictionaryto MedDRA5.1.   |
|--------|------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------|----------------------------------|
|        | Change(s)to themanufacturingprocessforthe activesubstance Change(s)to themanufacturingprocessforthe                                | 25/04/2003   | 22/07/2003   | Annex II | 1/0017 finished product          |
|        | 16_Changeinthebatchsizeoffinishedproduct                                                                                           | 19/03/2003   | 01/04/2003   |          | 1/0016                           |
|        | 20_Extensionofshelf-lifeasforeseenattimeof authorisation                                                                           | 19/12/2002   | 17/02/2003   | SmPC     | 1/0015                           |
|        | 11a_Changeinthenameofamanufacturerof the activesubstance                                                                           | 19/12/2002   | 17/02/2003   | Annex II | 1/0013                           |
| 1/0014 | 12_Minorchangeofmanufacturingprocessofthe activesubstance                                                                          | 23/01/2003   | 06/02/2003   |          |                                  |
|        | Annualre-assessment.                                                                                                               | 17/10/2002   | 28/01/2003   | AnnexIⅡI | S/0012                           |
|        | Change(s)to the manufacturingprocessforthe activesubstance                                                                         | 17/10/2002   | 21/10/2002   |          | 1/0011                           |
| 1/0008 | UpdateofSummaryofProductCharacteristics                                                                                            | 27/06/2002   | 03/10/2002   | SmPC     |                                  |
| I/0007 | Update of or change(s) to the pharmaceutical documentation                                                                         | 26/08/2002   | 12/09/2002   |          |                                  |

<div style=\"page-break-after: always\"></div>

| 1/0010   | 30_Changeinpacksizeforamedicinalproduct                                                                                                | 26/07/2002   | 10/09/2002   | SmPC, Labelling and PL   |        |
|----------|----------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|--------|
|          | 30_Change inpacksize for a medicinal product                                                                                           | 26/07/2002   | 10/09/2002   | SmPC, Labelling and PL   | 1/0009 |
|          | Updateoforchange(s)tothepharmaceutical documentation                                                                                   | 25/04/2002   | 24/05/2002   |                          | 1/0006 |
| 1/0001   | 11a_Changeinthenameofamanufacturerof the activesubstance                                                                               | 24/10/2001   | 28/02/2002   | Annex II                 |        |
|          | 12_Minorchangeofmanufacturingprocessofthe activesubstance                                                                              | 17/01/2002   | 07/02/2002   |                          | 1/0004 |
|          | 14_Changeinspecificationsofactivesubstance 24_Changeintestprocedure of active substance                                                | 17/01/2002   | 07/02/2002   |                          | 1/0003 |
|          | 14_Changeinspecificationsofactivesubstance 17_Change in specification ofthemedicinalproduct 24_Changeintestprocedureofactive substance | 13/12/2001   | 07/01/2002   |                          | 1/0002 |
| N/0005   | Minorchangeinlabellingorpackageleafletnot connected with the SPC(Art.61.3Notification)                                                 | 19/12/2001   | 10/04/2002   | Labelling and PL         |        |